Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
GTX Medical gains a new technology and loses a competitor
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Success still eludes pancreatic cancer pipeline
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Warning signs were always there for Novartis’s Avexis deal
High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
Novartis’s Narasimhan faces his first big test
Revelations of data manipulation might not be fatal, but they will hurt the chief exec’s attempted rebranding of Novartis as a more ethical pharma company.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Threats to Spinraza are mounting, but Biogen still has cards to play
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.